BBNX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Beta Bionics's net margin of --. Beta Bionics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Beta Bionics has a consensus price target of $26.43, signalling upside risk potential of 75.02%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 518.13%. Given that Perspective Therapeutics has higher upside potential than Beta Bionics, analysts believe Perspective Therapeutics is more attractive than Beta Bionics.

Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Beta Bionics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Beta Bionics's net income of -- is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Beta Bionics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 13.61x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -- compared to Beta Bionics's net margin of 16.85%. Beta Bionics's return on equity of -- beat Insulet's return on equity of 43.11%.

Beta Bionics has a consensus price target of $26.43, signalling upside risk potential of 75.02%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 17.05%. Given that Beta Bionics has higher upside potential than Insulet, analysts believe Beta Bionics is more attractive than Insulet.

Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Beta Bionics quarterly revenues are --, which are smaller than Insulet quarterly revenues of $597.5M. Beta Bionics's net income of -- is lower than Insulet's net income of $100.7M. Notably, Beta Bionics's price-to-earnings ratio is -- while Insulet's PE ratio is 46.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 9.57x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of -- compared to Beta Bionics's net margin of 0.27%. Beta Bionics's return on equity of -- beat Tandem Diabetes Care's return on equity of -37.18%.

Beta Bionics has a consensus price target of $26.43, signalling upside risk potential of 75.02%. On the other hand Tandem Diabetes Care has an analysts' consensus of $41.00 which suggests that it could grow by 102.07%. Given that Tandem Diabetes Care has higher upside potential than Beta Bionics, analysts believe Tandem Diabetes Care is more attractive than Beta Bionics.

Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.446, suggesting its more volatile than the S&P 500 by 44.616%.

Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

Beta Bionics quarterly revenues are --, which are smaller than Tandem Diabetes Care quarterly revenues of $282.6M. Beta Bionics's net income of -- is lower than Tandem Diabetes Care's net income of $755K. Notably, Beta Bionics's price-to-earnings ratio is -- while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 1.41x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Beta Bionics's net margin of -10.04%. Beta Bionics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

Beta Bionics has a consensus price target of $26.43, signalling upside risk potential of 75.02%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 224.07%. Given that Xtant Medical Holdings has higher upside potential than Beta Bionics, analysts believe Xtant Medical Holdings is more attractive than Beta Bionics.

Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Beta Bionics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Beta Bionics's net income of -- is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Beta Bionics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 0.62x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.